A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.

JL, Pujol; L, Greillier; C, Audigier-Valette; D, Moro-Sibilot; L, Uwer; J, Hureaux; F, Guisier; D, Carmier; J, Madelaine; J, Otto; V, Gounant; P, Merle; P, Mourlanette; O, Molinier; A, Renault; A, Rabeau; M, Antoine; MG, Denis; S, Bommart; A, Langlais; F, Morin; PJ, Souquet

doi:10.1016/j.jtho.2019.01.008

Public

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.

Shared by NobleBlocks on Jan 18, 2019 • 12:00 AM UTC

Authors:

Pujol JL

Greillier L

Audigier-Valette C

Abstract

Introduction This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum-etoposide chemotherapy.Methods Patients were randomized 2:1 to atezolizumab (1200 mg intravenously every 3 weeks) ...

Subject

Chemotherapy

SCLC

Programmed Cell Death Ligand 1

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!